2011年11月8日星期二

China Shineway Pharmaceutical 3q result

Revenue declined 14% yoyin 3Q compared to 12% yoy growth in 1H11, mainly driven by a slowdown inQingkailing sales coupled with price reduction amid price adjustments in the tendering process across regions.


mgmt expects volume to pick up in 4Q due to pent-up demand.

沒有留言:

發佈留言